Argentina 🇦🇷 ☀️

Está claro de dónde viene la campaña anti Argentina, los que no quieren verlo son ustedes

la diferencia está en que querer bajarle el show a tini en españa solo por ser argentina es un acto de xenofóbia... en cambio bajarle el show acá a la rosalia por insultar a nuestra gente y a nuestro país es un acto de patriotismo

Hola hermanos argentinos, queríamos decirles que muchos paraguayos los queremos de corazón y rechazamos totalmente esta campaña de odio que algunos intentan generar :D ¡rohayhu ❤️❤️❤️!

Los kukas viralizaron que en el país donde mas se come carne vacuna del MUNDO, comíamos carne de burro. Ahora están borraron todos los tuits porque se destapó que es una opereta del wokismo internacional.

Messi es el mejor jugador de la historia, pero nadie jamás jugó las finales como Di María en la historia del fútbol

Di Maria changed Argentina history

@fdzmurillo @AShmueil

Read the actual release, not the coverage.TRIUMPH-1: baseline 112.7 kg, BMI 40.0 → 28.3%. TRIUMPH-3: baseline 111.4 kg, BMI 40.4 → 22.6%.Same body weight. Same BMI. Six points gone.And the dose curve is flat where it matters: 9 mg gives 21.6%, 12 mg gives 22.6%. One point. Discontinuations go 9.8% → 13.5%.You pay four points of dropout for one point of weight.Semaglutide 7.2, approved and shipping, does 20.7% at 3.3%.Lilly's own release lists the submission as obesity, knee OA and sleep apnea. Cardiovascular isn't in it. MACE-3 hazard ratio came in at 1.12.This is the white hope.

$LLY Eli Lilly Delays Retatrutide Approval Filing to Q1 2027 Key Highlights: Filing delayed to Q1 2027 to gather additional manufacturing and quality-control data Phase 3 trials met primary endpoints in two additional studies Obesity + Type 2 diabetes patients: up to 20.8% average body weight loss Severe obesity + CVD patients: up to 22.6% average body weight loss Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon Common side effects: diarrhea, nausea, constipation TD Cowen estimates $3.8B in 2030 sales potential Novo Nordisk recently sued Lilly over alleged false advertising Expert Statement: “We believe we have the information necessary to file for approval globally for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and obstructive sleep apnea.” — Kenneth Custer, President of Lilly Cardiometabolic Health Impacts: $LLY | $HIMS | $NVO #LLY #EliLilly #Retatrutide #Obesity #GLP1 #WeightLoss #Cardiometabolic #MASH #FDA #ApprovalDelay #NovoNordisk #HIMS #NVO #TripleAgonist #Phase3

@fdzmurillo @AShmueil Amigo una observación. Puedo ver tus comentarios porque te estoy siguiendo. Pero cada ves que abro el hilo principal tus comentarios no se ven. No es la primera ves que me pasa. No se que porque me pasa eso. Parece como si estuvieras oculto.

Así empezaba la campaña anti Argentina. Los zurdos odian a la Argentina.

No hay que olvidar lo que dijo Mauricio Macri al ver la bandera que los jugadores argentinos desplegaro, luego del HISTÓRICO triunfo sobre Inglaterra, "Las Malvinas son Argentinas". Macri respondió sobre ese HITO histórico diciendo: "HICIERON UNA DE MÁS". Recuérdelo, argentino.

Podría haber citado a San Martín pero no, elige citar una frase que Churchill nunca dijo y encima en inglés. Qué tipo idiota, por Dios.

El soft power de la "ciencia argentina" se usa siempre contra la argentina

@batallan_lupe @AgustinLaje Lupe sin chicana. A que te referís con "la unidad nacionales que se está gestando en el interior del país"? Yo no veo absolutamente nada. Me podrías explicar mejor? Gracias!

@AgustinLaje Te mandaron a intentar fragmentar la unidad nacionales que se está gestando en el interior del país, putita sionista? Claro, porque un tejido social donde los distintos partidos vuelvan a buscar cosas en común es lo peor que les puede pasar a los cipayos como vos.

El kirchnerismo ha sido una pieza fundamental de la campaña anti-argentina: validaron el wokismo que hoy nos acusa de racistas; promovieron la idea de que los jugadores eran desclasados; fomentaron el odio contra Messi; y alimentaron desde la propia Argentina la mentira de que la Selección ganaba gracias a los árbitros y a los favores de la FIFA.

Pero cerrá el orto, perra satélite de Estados Unidos e Israel.

En el 2012 un grupo de intelectuales liberales firmaron un documento llamado “Malvinas una visión alternativa”. En el cual buscaban promover el reconocimiento de la posición de los kelpers contra los intereses argentinos. Hoy hablan de “paranoia nacionalista”.

$NVO has partnered with Crux to expand access to Wegovy and other FDA approved obesity medicines for employer sponsored health plans in the U.S. Through the collaboration, employers will have access to transparent, upfront pricing with no markups, rebates, or hidden fees. Eligible employees will receive Wegovy through licensed NovoCare Network pharmacies, while employers can help lower out of pocket costs using health reimbursement arrangements. Novo Nordisk said the partnership is designed to give employers more predictable drug costs while making it easier for eligible patients to access authentic, FDA approved obesity treatments. Link: businesswire.com/news/home/2026… #stocks #Investing

Basicamente es lo que vienen haciendo con Central y Di Maria.

🧵 Everyone is cheering Lilly's $LLY retatrutide readout today. I'll be the one saying it out loud: this is a fiasco dressed up as a win, and there are storm clouds forming on the horizon for Lilly's obesity franchise. Let's look at what actually landed on July 23, 2026: TRIUMPH-2 (obese patients with type 2 diabetes, n=1,152): 20.8% weight loss at 12 mg. TRIUMPH-3 (severe obesity + established cardiovascular disease, n=1,949): 22.6% weight loss at 12 mg. Now compare with what Lilly has been selling for months from TRIUMPH-1: 28.3% at 80 weeks, and the "up to 30.3%" headline from the 104-week extension. The market has been pricing retatrutide as the drug that would leave Wegovy and even Lilly's own Zepbound in the dust. Today, that narrative broke. Nobody is willing to say it, so I will. 1️⃣ The 28–30% number only works in the cleanest possible cohort — obese patients without diabetes, without cardiovascular disease, with long treatment duration. The moment you put retatrutide in front of the populations that will actually receive it commercially — diabetics and cardiac patients — the effect collapses by 5 to 8 percentage points. That is not a rounding error. That is the difference between a category killer and just another GLP-1. 2️⃣ In diabetics, retatrutide is barely differentiated. 20.8% vs semaglutide 7.2 mg (Wegovy HD) at ~19% and tirzepatide (Zepbound) at ~22.5%. Lilly is competing against its own already-approved Zepbound and losing on paper in the T2D setting. Think about that: the "next-gen" molecule underperforms the current-gen in the largest addressable subpopulation. 3️⃣ The silent bomb of today's release: "no clear cardiovascular edge yet." This is the line nobody wants to highlight. TRIUMPH-3 was not designed just for weight loss — it was Lilly's shot at replicating what Novo Nordisk achieved with SELECT (20% MACE reduction with semaglutide in patients with established CVD). Retatrutide did not deliver that signal. Without a clean CV outcomes story, the premium pricing argument evaporates and payers will not roll over. 4️⃣ The stock action confirms the story, if you know how to read it. $LLY closed at $1,187 today, up +3.5%. That is a courtesy move, not a breakout. A true franchise-defining readout would have printed +8 to +12%. The tape is telling you the sell-side is quietly recalibrating peak sales estimates downward, even while the press releases stay glossy. 5️⃣ Lilly's comparison games are catching up with them. For over a year the company has benchmarked retatrutide against Wegovy 2.4 mg — the old dose. Novo now has semaglutide 7.2 mg approved and delivering ~19% mean loss, with responder subgroups touching 27.7%. The real delta between retatrutide and Novo's best weapon is not the 13-point gap Lilly likes to imply. It is closer to 1 to 3 points in diabetics and ~4 points in CVD patients. That is not a moat. That is a puddle. 6️⃣ The strategic implication: Lilly filed for retatrutide expecting to command premium pricing on a superiority argument. Today's data forces a repricing of that thesis. Meanwhile Novo is closing the efficacy gap with dose escalation, oral formulations are coming from multiple players in 2026–2027, and the entire GLP-1 category is heading toward commoditization faster than Wall Street has priced in. Bottom line without spin: retatrutide is not the sledgehammer it was sold as. It is a very good drug that looks average in the populations that pay the bills. The 28–30% headline was the ceiling, not the mean. And the CV story — the one that would have justified everything — did not show up today. The market is choosing not to see it. That does not mean it is not there. Storm clouds on the horizon for $LLY.

Tome medidas @pabloquirno esto es gravísimo. Deje de boludear en Twitter y póngase a trabajar.